semaglutide flyer Design job. Flyer brief for a company in United States We're very happy to announce
Description
Semaglutide is available for the treatment of overweight and obesity in people with or without type 2 diabetes (Kadowaki et al., 2022)
In REWIND, dulaglutide use reduced the HbA1c value by 0.61% and body weight by 1.46 kg compared with placebo (Kristensen et al., 2019)
Checkpoint Weeks 5-8 (0.5 mg) What clinical trials show Early appetite changes possible
Stable up to 24 months
